Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Van Cutsem, E.
Right arrow Articles by Maroun, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Van Cutsem, E.
Right arrow Articles by Maroun, J.
The Oncologist, Vol. 6, Suppl 4, 1-2, August 2001
© 2001 AlphaMed Press

SUPPLEMENT

Thymidine Phosphorylase (TP) Activation: Convenience Through Innovation

Eric Van Cutsema, David Cunninghamb, Paulo M. Hoffc, Jean Maround

a University Hospital Gasthuisberg, Leuven, Belgium; b Gastrointestinal and Lymphoma Units, The Royal Marsden Hospital, London and Surrey, UK; c Albert Einstein Hospital, São Paulo, Brazil; d Ottawa Regional Cancer Centre, Ottawa, Canada

Correspondence: Eric Van Cutsem, M.D., Ph.D., University Hospital Gasthuisberg, Herestraat 49, BE - 3000 Leuven, Belgium. Telephone: 32-16-344-225; Fax: 32-16-344-419; e-mail: eric.vancutsem{at}uz.kuleuven.ac.be

The management of patients with metastatic colorectal cancer most commonly involves treatment with 5-fluorouracil (5-FU), administered with or without leucovorin (LV) as an i.v. bolus or protracted infusion. Protracted infusion schedules have demonstrated superior efficacy compared with bolus regimens [1], but are associated with greater inconvenience and cost. Complications can also arise from the use of indwelling catheters [2].

The oral fluoropyrimidines have been developed to avoid some of these problems. Among the most promising of the oral agents is capecitabine (Xeloda®), a novel fluoropyrimidine carbamate that mimics continuous-infusion 5-FU. Capecitabine is metabolized to 5-FU via a three-step enzymatic cascade, the third step of which is mediated by thymidine phosphorylase (TP). TP, also known as platelet-derived endothelial cell growth factor, is correlated with poor prognosis, fast malignant growth, aggressive invasion potential, and anti-apoptotic properties. Preclinical studies have shown that TP is significantly more active in tumor tissue than in adjacent healthy tissue [3]. Capecitabine exploits the higher intratumoral concentrations of TP to achieve tumor-selective generation of 5-FU, resulting in increased concentrations of 5-FU in the tumor [4]. This tumor selectivity potentially reduces systemic exposure to 5-FU, improving efficacy and enhancing tolerability.

Capecitabine has demonstrated considerable single-agent activity as first-line treatment for metastatic colorectal cancer. Data from two large, randomized, phase III clinical trials demonstrated that capecitabine results in a significantly superior tumor response rate compared with i.v. 5-FU/LV (Mayo Clinic regimen) and equivalent time to disease progression and overall survival [5]. Capecitabine also demonstrated an improved safety profile compared with i.v. 5-FU/LV. On the basis of these trials, capecitabine has recently been approved in Europe, the U.S., Canada, and numerous other countries for the first-line treatment of metastatic colorectal cancer.

Another important advance in the treatment of colorectal cancer has been the introduction of two new agents, irinotecan and oxaliplatin. Irinotecan monotherapy is now an established treatment for patients with colorectal cancer that has progressed with prior 5-FU-based therapy [6, 7]. More recently, phase III trials have shown that the addition of irinotecan to bolus or infused 5-FU/LV in the first-line setting results in significantly improved survival [8, 9]. The addition of oxaliplatin to 5-FU/LV has also been shown to increase activity in both the first- and second-line settings [10-13], and the use of oxaliplatin, particularly in Europe, is widespread.

As an oral fluoropyrimidine with high single-agent activity and a favorable safety profile, capecitabine potentially provides a more effective, convenient, and better-tolerated alternative to 5-FU/LV in these combination regimens. Phase I/II trials have already evaluated capecitabine in combination with oxaliplatin and irinotecan, with encouraging results. In addition, capecitabine is being investigated in combination with radiotherapy in rectal cancer. There is a strong preclinical rationale for exploring this combination, as TP activity in the tumor is upregulated by irradiation. Phase I and II trials have shown that the combination is feasible, and capecitabine may have the potential to replace i.v. 5-FU as a combination partner for radiotherapy in the treatment of rectal cancer [14].

This supplement provides an in-depth review of a large, European meeting in which leading experts gathered to discuss the state-of-the-art in the treatment of colorectal cancer [15]. Topics covered include the clinical trial data of irinotecan and oxaliplatin, the different strategies for incorporating these novel agents into clinical practice, and the phase III data for capecitabine as first-line monotherapy. The supplement also includes discussion on the potential of capecitabine in the future as a combination partner for irinotecan, oxaliplatin, and radiotherapy in patients with colorectal cancer, and as monotherapy or combination therapy in a range of other tumor types.


   REFERENCES
Top
 References
 

  1. Meta-Analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301–308.[Abstract/Free Full Text]
  2. Partridge S, Leslie M, Irvine A. Infusional 5-fluorouracil can be a pain in the neck: a case for repositioning displaced Hickman lines. Clin Oncol (R Coll Radiol) 1999;11:274–276.[Medline]
  3. Miwa M, Ura M, Nishida M et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274–1281.
  4. Schüller J, Cassidy J, Dumont E et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000;45:291–297.[CrossRef][Medline]
  5. Hoff PM. Capecitabine as first-line treatment for colo-rectal cancer (CRC): integrated results of 1207 patients (pts) from 2 randomized, phase III studies. On behalf of the Capecitabine CRC Study Group. Ann Oncol 2000;11(suppl 4):60a.
  6. Cunningham D, Pyrhönen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413–1418.[CrossRef][Medline]
  7. Rougier P, Van Cutsem E, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407–1412.[CrossRef][Medline]
  8. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905–914.[Abstract/Free Full Text]
  9. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041–1047.[CrossRef][Medline]
  10. de Gramont A, Vignoud J, Tournigand C et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997;33:214–219.
  11. Maindrault-Goebel F, Louvet C, André T et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). Eur J Cancer 1999;35:1338–1342.
  12. de Gramont A, Figer M, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938–2947.[Abstract/Free Full Text]
  13. Giacchetti S, Perpoint B, Zidani R et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136–147.[Abstract/Free Full Text]
  14. Reese T, Tanner J, Frings S et al. Capecitabine combined with simultaneous radiotherapy in rectal cancer: a phase-I-study. Int J Radiat Oncol Biol Phys 2000;48(suppl 3):120–121.
  15. Van Cutsem E, Cunningham D, Hoff P.M. et al., eds. Incorporating Oral Capecitabine into the Treatment of Colorectal Cancer. The Oncologist 2001;6(suppl 4):1–39.[Free Full Text]
Received July 9, 2001; accepted for publication July 19, 2001.





This Article
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Van Cutsem, E.
Right arrow Articles by Maroun, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Van Cutsem, E.
Right arrow Articles by Maroun, J.

HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS